Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes Bunka included this because of Canopy's and others woes.
'Certain types of packaging, such as polystyrene, can also absorb between 60% and 100% of the THC within (LINK), if the consumer products have not been stabilized such as is possible with DehydraTECH. Consumers have legitimate concerns about inventories of hemp or cannabis oil or plant matter being used to create products, and whether their potency is as advertised.'
It is interesting stockman! WEED paid C$430 million for EBBU who was supposed to have this great proprietory tech. for infusing beverages with cannabis. It turns out their tech was just a variation on known emulsification tech. and the US Patent office wouldn't issue EBBU any patents. And now we see how it works, at least in aluminum cans. I think Canopy may have to write down almost their complete investment in EBBU and also all the canned inventory is a total loss. Anybody want to buy a barely used canning plant? Or perhaps Canopy would like to license a technology that works and has been through extensive stability and safety testing at the National Research Council of Canada.
Whoops! Should have gone with Lexaria instead of grossly overpaying for EBBU to gain an unpatentable technology that sucks!
https://ca.finance.yahoo.com/news/cans-suck-the-thc-buzz-out-of-pot-drinks-where-does-that-leave-canopy-growth-131708432.html
Early 2020 was his latest timeline for Altria news
I'm curious as to why they don't say who is getting the options.
A devastating short report on Canopy Growth can be downloaded here: https://smartmoneygains.com/sector-watch/canopy-growths-smoke-and-mirrors/?fbclid=IwAR1Q6rTpxBOvhSFnKsO8XAzCW36sUu5JlmRoEoJuUbR7yH3a1pGYRvNg9yE
Oh, do tell! What's the question?
on! is now available in 15,000 stores nationally, including 3 of the top 5 chains for smokeless volume.
Helix expects to begin manufacturing on! at the Richmond Manufacturing Center in first-quarter 2020.
Just read through Altria's financials, no hints in there!
It will be interesting to see what if any forward-looking statements Altria makes tomorrow during earnings report in regards to progress towards a smokeless future.
Altria is set to release their earnings on Jan 30 so maybe we'll hear something re: the Lexaria deal shortly after that.
Here is a very detailed analysis of MOU.
https://seekingalpha.com/article/4319256-altria-why-next-decade-will-make-break-company?utm_medium=email&utm_source=seeking_alpha
I'm not sure why, as he doesn't seem to have a production facility or a co-packer to make cannabis beverages, and I haven't heard of him applying to Health Canada for a license to produce anything. He's missed the boat and I'm a bag-holder.
BEER up 25% this morning. +.02 cents
Some of us here are older and we need our 'quiet' time. LOL
Yes the OS is 80,720,879, not fully diluted.
Chris Bunka owns over 13 million shares.
We know that the Altria/Lexaria/NRC workgroup is testing various product formats, under investigation at the National Research Council should be powders, tablets/caps, lozenges and nicotine pouches e.g. On! All in several dosages.
https://www.marketwatch.com/story/altria-stock-boosted-by-news-of-acquisition-of-nicotine-pouch-business-on-2019-06-03
Altria is going to use DehydraTECH to make their pouches the best on the market, with the lowest manufacturing cost.
Nice close in Canuckland .70 up .09, but volume low.
This explains a lot.
Lexaria’s workgroup, including extensive ongoing R&D performed by Canada’s National Research Council on our behalf, continues to work closely with Altria to determine the appropriateness of the DehydraTECH technology for potential use in the global tobacco industry, via several product formats currently under investigation. Lexaria is making important, significant progress in its goal of achieving reduced-risk methods of nicotine delivery.
https://www.lexariabioscience.com/news/lexaria-bioscience-ceo-discusses-strategic-outlook/
67,000 bid @ .65 now!
Bids pilling up on Canadian side, 42,500 bid at .65
Ask now .70 in Great White North, only 1000 shares.
There is no category for drink powders it seems. Yes, Hill Street is supposed to make the powders in Canada, whether it will be branded as ChrgD+ I don't know.
Thanks, Brian Quigley,
'From Richmond, Virginia, Board Member of Lexaria & Advisor to The Boldt Runners Corporation, Brian Quigley said "This combination of superior science from Lexaria and a unique and strong branded proposition that Cannadips offers with its CBD pouch platform is a winning combination We are excited to be developing a category of products with best in class science to provide adult consumers the simple choice of a better product and a better alternative to tobacco and nicotine."
Altria's nomination to our BOD is already earning his keep!
https://www.lexariabioscience.com/news/lexarias-appoints-former-altria-group-senior-executive-and-operating-company-chief-to-board-of-directors/
I'm immediately selling everything and buying back at .14. Thank you for your ongoing technical analysis all4.
Surging volume says you're wrong.
OK thanks, we got it the first time!
What do we need for a share price to attain Chris' dream of listing on the big board in the US?
Today the biggest volume day since February!
Summary
2019 was the best year of corporate progress that Lexaria has ever experienced. We started the year with a major announcement with one of the world’s largest companies evaluating our technology, including a negotiated royalty fee applicable to world-wide sales of products utilizing DehydraTECH: our biggest licensing deal ever. We hope to announce ongoing progress with this relationship early in 2020, and we also hope to attract new Fortune 500 CPG licensees in the coming year as well.
Through a partner, we opened a new US facility capable of manufacturing at a potential current rate of up to 200,000 servings of enhanced DehydraTECH powders per day, and we expect this to begin generating licensing as well as fee-for-goods and services revenues for us in early 2020. We signed new corporate clients in the cannabinoid sector throughout the year, many of whom expect to commence retail operations in 2020, and we are increasingly attracting the interest of larger, more established MSOs in the field.
We received approval from Health Canada to open and operate our new cannabis R&D facility in our head office newly-built in Kelowna, Canada, through which we intend to continue to broaden our formulation and IP development and increasingly attract Canadian DehydraTECH licensees with the recent dawn of the legal edibles sector in Canada.
We received our first medical claim patent grants, opening the door to increased likelihood of pharmaceutical operations to come. Lexaria continues to develop its proprietary drug delivery platform and is working on commercial release of DehydraTECH version 2.0 sometime in 2020 with even faster delivery than ever before.
We continue to face headwinds that we need to overcome. We need to evidence wider adoption of our technology within the cannabinoid industries. We also need to provide evidence to the investing public that Lexaria is not a cannabis production company but instead should be distinguished and valued as a leading biotech company with a patented, proprietary drug delivery technology with applications to many industries.
Lexaria expects strong, sustainable revenue growth in 2020 and beyond. We are working towards an application for a national stock exchange listing; hoping to announce additional Fortune-500 relationships; and significant new client relationships.
We are working diligently so that, when we look back on 2020 we remember it only as, “It was the best of times…”
Of course, Lexaria has been working with Canada's National Research Council on DehydraTECH since Feb. 2017.
https://www.lexariabioscience.com/news/lexaria-bioscience-completes-initial-project-with-canadas-national-research-council/
This and the fact that Altria nominated Brian Quigley to Lexaria's BOD help keep me invested.
https://www.lexariabioscience.com/news/lexarias-appoints-former-altria-group-senior-executive-and-operating-company-chief-to-board-of-directors/
I like that Canada National Research Council + Lexaria + Altria = ?
"Lexaria’s workgroup, including extensive ongoing R&D performed by Canada’s National Research Council on our behalf, continues to work closely with Altria to determine appropriateness of the DehydraTECH technology for potential use in the global tobacco industry, via several product formats currently under investigation. Lexaria is making important, significant progress in its goal of achieving reduced-risk methods of nicotine delivery."
Nothing about what they did to increase shareholders' values? LOL
Remember Lexaria's laboratory is licensed and inspected by Health Canada.
https://www.lexariabioscience.com/news/lexaria-bioscience-receives-cannabis-rd-license-from-health-canada/
0 Shares traded in The Great White North!
My God! That lunchroom is just stunning! I'm going all-in now. LOL